{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.1","upperLimit":"31.8","value":"70"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"76"}]}],"title":"OS at 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"61"}]}],"title":"OS at 12 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"Overall Survival (OS): time from the date of first infusion to the date of documented death","groups":[{"description":"Plitidepsin 5 mg/m2 given as a 3-hour i.v. infusion every two weeks.","id":"OG000","title":"Plitidepsin"},{"description":"Plitidepsin 5 mg/m2 given as a 3-hour i.v. infusion every two weeks plus 20 mg of oral dexamethasone every day on days 1 to 4 of each cycle, starting at the same time than the plitidepsin infusion.","id":"OG001","title":"Plitidepsin + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Per protocol - Only 21 of 32 and 8 of 19 enrolled patients were evaluable (analyzed patients. For patient of group plitidepsin + dexamethasone the median overall survival could not be calculated due to follow-up short duration. The survival rates at 6 and 12 months are provided instead.","reportingStatus":"POSTED","timeFrame":"Start of treatment to death. At each patient visit while on treatment, then every 3m during follow-up. Median OS and OS rates at 6 months and 12 months were assessed.","title":"Number of Patients With Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"percentage patients"}